

Gregory A Eschenauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/464720/publications.pdf>

Version: 2024-02-01

45
papers

1,509
citations

394286

19
h-index

315616

38
g-index

46
all docs

46
docs citations

46
times ranked

2852
citing authors

#	ARTICLE	IF	CITATIONS
1	Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. <i>Clinical Infectious Diseases</i> , 2021, 73, e445-e454.	2.9	350
2	Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab268.	0.4	3
3	Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 76.	1.5	12
4	Evolution of Equations for Estimating Renal Function and Their Application to the Dosing of New Antimicrobials. <i>Annals of Pharmacotherapy</i> , 2020, 54, 496-503.	0.9	4
5	Macrolide-resistant <i>Mycoplasma pneumoniae</i> pneumonia in transplantation: Increasingly typical?. <i>Transplant Infectious Disease</i> , 2020, 22, e13318.	0.7	2
6	Antifungal stewardship: Still catching up? Commentary on "Variability in antifungal stewardship strategies among Society for Healthcare Epidemiology of America (SHEA) Research Network facilities". <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 590-591.	1.0	0
7	Incorporating preauthorization into antimicrobial stewardship pharmacist workflow reduces <i>Clostridioides difficile</i> and gastrointestinal panel testing. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1136-1141.	1.0	6
8	578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, S354-S354.	0.4	2
9	792. Evaluation of Persistent Diarrhea and Recurrence Following Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, S439-S440.	0.4	0
10	Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients. <i>JAMA Internal Medicine</i> , 2019, 179, 1519.	2.6	82
11	1035. Implementation of an Antimicrobial Stewardship Program-Led, Multifactorial Pneumonia Diagnosis and Treatment Bundle. <i>Open Forum Infectious Diseases</i> , 2019, 6, S364-S364.	0.4	0
12	1056. Evaluation of Clinical Outcomes Following Implementation of Real-Time Stewardship Team Interventions for Multi-Drug-Resistant Organisms. <i>Open Forum Infectious Diseases</i> , 2019, 6, S373-S373.	0.4	0
13	A multicentre stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of community-acquired pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1402-1407.	1.3	32
14	Survival in Patients with <i>Candida glabrata</i> Bloodstream Infection Is Associated with Fluconazole Dose. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	11
15	1071. Impact of Standard vs. Prolonged Courses of Antibiotics for the Treatment of Uncomplicated <i>Staphylococcus aureus</i> Bacteremia (SAB) in Patients With Hematologic Malignancies. <i>Open Forum Infectious Diseases</i> , 2018, 5, S320-S321.	0.4	1
16	869. Evaluation of Broad-Spectrum Antibiotic De-Escalation in Patients with Health-Care Associated Pneumonia (HCAP) and No Microbiological Diagnosis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S23-S24.	0.4	1
17	1876. Patient- and Hospital-Level Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients: A Multi-Hospital Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, S536-S537.	0.4	0
18	2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, S634-S634.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	13
20	Multicenter Stewardship Initiative to Decrease Excessive Duration of Antibiotic Therapy for the Treatment of Community-Acquired Pneumonia (CAP). <i>Open Forum Infectious Diseases</i> , 2017, 4, S63-S64.	0.4	0
21	Disease-based antimicrobial stewardship: a review of active and passive approaches to patient management. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3232-3244.	1.3	18
22	Antifungal Prophylaxis in Lung Transplant Recipients. <i>Transplantation</i> , 2016, 100, 1815-1826.	0.5	35
23	Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View. <i>Seminars in Dialysis</i> , 2016, 29, 204-213.	0.7	10
24	Effect of an antimicrobial stewardship intervention on outcomes for patients with <i>Clostridium difficile</i> infection. <i>American Journal of Infection Control</i> , 2016, 44, 1539-1543.	1.1	10
25	Targeted Versus Universal Antifungal Prophylaxis Among Liver Transplant Recipients. <i>American Journal of Transplantation</i> , 2015, 15, 180-189.	2.6	64
26	Doripenem MICs and ompK36 Porin Genotypes of Sequence Type 258, KPC-Producing <i>Klebsiella pneumoniae</i> May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1797-1801.	1.4	25
27	Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1068-1074.	0.9	25
28	Impact of an antimicrobial stewardship-led intervention for <i>Staphylococcus aureus</i> bacteraemia: a quasi-experimental study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv256.	1.3	30
29	Calming the "Perfect Storm" in Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: A Call for a More Balanced Discussion. <i>Clinical Infectious Diseases</i> , 2015, 60, 670-671.	2.9	3
30	Bringing the "Power" to Cerner's PowerChart for Antimicrobial Stewardship. <i>Clinical Infectious Diseases</i> , 2014, 59, 416-424.	2.9	19
31	Real-World Experience with Echinocandin MICs against <i>Candida</i> Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1897-1906.	1.4	59
32	The Evolving Role of Antifungal Susceptibility Testing. <i>Pharmacotherapy</i> , 2013, 33, 465-475.	1.2	22
33	Fluconazole versus an echinocandin for <i>Candida glabrata</i> fungaemia: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 922-926.	1.3	42
34	Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Infections among Solid Organ Transplant Recipients. <i>PLoS ONE</i> , 2012, 7, e52349.	1.1	118
35	Supratherapeutic oseltamivir levels during continuous dialysis: an expected risk. <i>Intensive Care Medicine</i> , 2011, 37, 371-371.	3.9	5
36	The impact of delaying the initiation of appropriate antifungal treatment for <i>Candida</i> bloodstream infection. <i>Medical Mycology</i> , 2010, 48, 436-439.	0.3	27

#	ARTICLE	IF	CITATIONS
37	Carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteremia: factors correlated with clinical and microbiologic outcomes. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 180-184.	0.8	92
38	Antifungal prophylaxis in liver transplant recipients. <i>Liver Transplantation</i> , 2009, 15, 842-858.	1.3	64
39	Evolving role of early antifungals in the adult intensive care unit. <i>Critical Care Medicine</i> , 2009, 37, 1580-1593.	0.4	28
40	To Test or Not To Test: a Cost Minimization Analysis of Susceptibility Testing for Patients with Documented <i>Candida glabrata</i> Fungemias. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1884-1888.	1.8	27
41	Comparison of echinocandin antifungals. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 71-97.	0.9	164
42	Compliance with Institutional Guidelines on the Use of Vancomycin in a Medical Intensive Care Unit. <i>Hospital Pharmacy</i> , 2006, 41, 749-753.	0.4	2
43	Pharmacology and therapeutic uses of theanine. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 26-30.	0.5	49
44	Antibiotic Allergy. <i>New England Journal of Medicine</i> , 2006, 354, 2293-2294.	13.9	3
45	Azithromycin-Warfarin Interaction: Are We Fishing with a Red Herring?. <i>Pharmacotherapy</i> , 2005, 25, 630-631.	1.2	3